COMPARE Clinical Trial

 
  1. COMPARE Clinical Trial 12-Month Full Cohort Results presented by Sabine Steiner, MD. LINC 2020.

12-Month full cohort results from COMPARE1, the world’s first head-to-head, prospective, multi-center, randomized controlled Trial (1:1) comparing the low dose paclitaxel RANGER™ DCB (2 µg/mm2) to the higher dose paclitaxel IN.PACT™ DCB (3.5 µg/mm2). Primary endpoints were binary primary patency and freedom from major adverse events. 

Presented at LINC 2020 by Sabine Steiner, MD and simultaneously published in European Heart Journal

COMPARE Manuscript

12-Month full cohort results from COMPARE Trial

 

Compare Trial 12-Month Kaplan-Meier Primary Patency Results
* Log-rank p-value compares the entire K-M curves from time zero to full one year follow-up window.
PRIMARY ENDPOINTS RANGER IN.PACT p-value
Binary Primary Patency 83.0%
(156/188)
81.5%
(141/173)
Pnon-inferiority<0.01
Freedom from major adverse events 91.0%
(182/200)
92.6%
(175/189)
Pnon-inferiority<0.01
Both primary endpoints met.
 
TRIAL DETAILS RANGER
(n=207)
IN.PACT
(n=207)
p-value
Paclitaxel dose density 2.0 µg/mm2 3.5 µg/mm2 N/A
Average total paclitaxel dose per patient in trial 6,971 µg 13,035 µg <0.0001
Excipient TransPax™
citrate ester
Urea N/A

 

BASELINE CHARACTERISTICS RANGER
(n=207)
IN.PACT
(n=207)
p-value
Age (year) 68.2 68.4 0.79
Female 38.2% 36.2% 0.68
Current/Former Smoker 77.3% 75.3% 0.63*
Total Occlusions 41% 43% 0.62
Total Occlusion Length 131 mm 113 mm 0.23
Target Lesion Length 124 mm 128 mm 0.65
Moderate to Severe Calcification** 50% 57% ***
Diabetics 31% 37% 0.18
* p-value based on entire distribution. Never, Former or Current Smokers
** PACSS Grade 3/4 may be considered similar to moderate/severe calcification
*** p-value for entire distribution of PACSS Calcium Grades 0, 1, 2, 3, 4 calcium for RANGER vs IN.PACT. p-value was 0.20.

  

 

12 MONTH KEY RESULTS RANGER
(n=207)
IN.PACT
(n=207)
p-value
Mortality: All Cause 2.5% 1.6% 0.73
Mortality: Device or procedure related 0% 0% N/A
CD-TLR 9.0% 7.4% 0.59
 

Definitions

Primary safety endpoint — composite of freedom from device and procedure-related death through 30-days and freedom from major target limb amputation and CD-TLR through 12 months post index-procedure.

Primary efficacy endpoint — primary patency at 12 months defined as absence of clinically-driven target lesion revascularization (CD-TLR) or binary restenosis determined as a peak systolic velocity ratio > 2.4 evaluated by duplex ultrasound core laboratory analysis.

CD-TLR — a reintervention performed for ≥ 50% diameter stenosis (confirmed by angiography) within ± 5 mm proximal and/or distal to the target lesion after documentation of recurrent clinical symptoms of PAD (increase of 1 Rutherford class or more) and/or drop of ABI (≥20% or ≥0.15 when compared to maximum early postprocedural level).

 

CAUTION: Ranger is an Investigational Device. Limited by Federal (or US) law to investigational use only. Not available for sale. 

 

Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Top